Hypofractionated Whole-Brain Radiotherapy Targets a Hard-to-Treat Melanoma Brain Metastasis Population
A randomized phase II study in Russia is testing whether a shorter, more intense whole-brain radiotherapy schedule can match or outperform standard treatment for patients with disseminated cutaneous or mucosal melanoma and multiple brain metastases. The trial, known as HALT-METS, compares hypofractionated whole-brain radiotherapy at 6.5 Gy per fraction for a total dose of 26 Gy against conventional whole-brain radiotherapy at 3 Gy per fraction for a total dose of 30 Gy.
The question behind the study is straightforward and clinically consequential. Melanoma brain metastases remain difficult to control, and whole-brain radiotherapy often has to balance intracranial palliation against the risk of neurotoxicity, fatigue, and decline in cognitive function. A shorter course could reduce treatment burden and may improve tolerability if the larger per-fraction dose can still preserve local control. A longer course, by contrast, may remain preferable if it better protects the central nervous system from injury while maintaining acceptable disease control.
This is not a theoretical exercise in dose mathematics. In patients already living with intracranial metastatic disease, the difference between a 12- to 14-day treatment course and an 8-day schedule can affect logistics, symptom burden, and the practical feasibility of completing therapy.
Trial Design Centers on Toxicity, Survival, and Brain Control
HALT-METS is a single-center, prospective, open-label, randomized trial. The study enrolled 50 participants and used parallel assignment, with no masking. Treatment began on 2022-07-01, and both primary completion and study completion are listed as 2026-04-01. The record identifies the trial as completed, with no results posted yet.
Eligibility was intentionally focused on a population with significant intracranial disease burden. Participants had to be adults older than 18 years with at least five brain metastases, or fewer lesions if stereotactic radiosurgery was not indicated. Investigators also required morphologic verification of the primary tumor, or verification of the metastatic lesion if the primary site was unknown, plus signed informed consent. Functional reserve had to be adequate, with Karnofsky Performance Status of at least 60%, and patients needed no contraindication to external-beam radiotherapy. Prior brain radiotherapy, severe somatic illness, pregnancy, and psychiatric disorders were exclusion criteria.
The study population therefore reflects a group in whom treatment choices are often constrained by disease extent and declining neurologic reserve. Whole-brain radiotherapy remains a common option when lesions are too numerous for focal approaches, but the tradeoff is familiar: broader intracranial coverage comes with a heavier burden of exposure to normal brain tissue.
Fraction Size Drives the Biological Rationale
The experimental arm delivers 6.5 Gy per fraction every other day, three times per week, for four fractions over eight days. The control arm gives 3 Gy daily, five times per week, for ten fractions over 12 to 14 days. Both regimens aim to treat the entire brain, but they do so through very different radiobiologic pathways.
Larger fraction sizes can increase the dose intensity delivered over a shorter time, which may matter in a rapidly progressive metastatic setting. At the same time, high fraction sizes may raise concern for late effects in central nervous system tissue, especially when survival is long enough for delayed toxicity to emerge. The study is built around that tension. It asks whether the shorter schedule can preserve disease control without pushing acute or delayed adverse effects beyond acceptable limits.
The investigators framed tolerability broadly. Primary outcomes include acute and late radiation toxicity across the central nervous system, skin, ear, and mucosa, using RTOG acute and late morbidity criteria. The protocol also tracks dizziness, headache, insomnia, tremor, peripheral motor neuropathy, peripheral sensory neuropathy, depression, dry eye, hearing impairment, alopecia, skin erythema, memory impairment, concentration impairment, and cognitive impairment, each graded on standard toxicity scales.
That breadth is clinically appropriate. Whole-brain radiotherapy does not injure only the target volume in an abstract sense; it can alter cognition, fatigue, balance, sensory function, mood, and daily performance. In melanoma brain metastases, where prognosis is often guarded and neurologic symptoms can already be substantial, even modest toxicity differences can affect quality of life in a way that standard survival statistics may miss.
Survival and Local Control Remain Secondary But Essential Readouts
Overall survival from the start of radiotherapy is listed as a secondary endpoint, measured with Kaplan-Meier analysis. Local control is another secondary measure, assessed by MRI-based volumetric response. The response schema is detailed: complete response, near-complete response defined as at least a 90% volume reduction, partial response defined as a reduction of at least 30% but less than 90%, positive stabilization, negative stabilization, and progression.
Those imaging criteria matter because melanoma metastases can be biologically aggressive and may not respond in a uniform way across all intracranial lesions. Volumetric MRI assessment is better suited than a simple binary readout when investigators want to understand whether the entire intracranial burden is being stabilized or merely partially suppressed. In a setting like this, local control is not a cosmetic endpoint. It is tied directly to the likelihood of neurologic deterioration, corticosteroid exposure, repeat hospitalization, and loss of independence.
The study also embeds a practical comparison between treatment convenience and expected toxicity. A four-fraction regimen is easier to complete for many patients with advanced metastatic disease, especially if neurologic symptoms, travel burden, or frailty make longer treatment courses difficult. Yet convenience alone cannot justify a dose change in the brain unless intracranial control remains durable and delayed injury does not rise.
What the Completed Record Can and Cannot Show
The trial is listed as completed, but no results have been posted in the ClinicalTrials.gov record. That leaves the protocol itself as the clearest window into the study’s clinical intent. The design suggests a deliberate attempt to test whether a compact whole-brain schedule can hold its own against a more conventional regimen in a population with multiple melanoma brain metastases and limited physiologic reserve.
The sample size was small, which is expected for a single-center phase II trial but still limits broad inference. The open-label design also leaves room for bias in symptom reporting and clinical decision-making, particularly for endpoints such as fatigue, cognitive change, dizziness, or mood symptoms. The record does not provide the outcome data needed to determine whether the experimental approach improved survival, preserved cognition, or reduced toxicity.
Even without results, the clinical question is sharply defined. If the hypofractionated schedule proves tolerable and offers comparable brain control, it could shorten treatment and reduce burden for a population that often has little margin for prolonged therapy. If toxicity rises or local control weakens, standard fractionation would keep its place as the safer default for patients with extensive melanoma brain metastases.